Critical Contrast: Nuvalent (NASDAQ:NUVL) and Scinai Immunotherapeutics (NASDAQ:SCNI)

Nuvalent (NASDAQ:NUVL) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Nuvalent and Scinai Immunotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1	0	16	1	2.94
Scinai Immunotherapeutics	1	0	0	0	1.00

Nuvalent currently has a consensus target price of $140.29, suggesting a potential upside of 37.38%. Given Nuvalent’s stronger consensus rating and higher possible upside, analysts clearly believe Nuvalent is more favorable than Scinai Immunotherapeutics.

Valuation & Earnings

This table compares Nuvalent and Scinai Immunotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38 million	($6.06)	-16.85
Scinai Immunotherapeutics	$1.31 million	1.25	-$8.31 million	($9.57)	-0.05

Scinai Immunotherapeutics has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvalent and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Scinai Immunotherapeutics	N/A	N/A	N/A

Risk and Volatility

Nuvalent has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500.

Insider & Institutional Ownership

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Scinai Immunotherapeutics beats Nuvalent on 7 of the 13 factors compared between the two stocks.

About Nuvalent

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.